Moxifloxacin is a fluoroquinolone antibacterial agent used for specific susceptible bacterial infections. Labeling contains boxed warnings for disabling adverse reactions and recommends reserving use for situations where benefits outweigh risks or where no alternatives exist for some uncomplicated infections. It is a human prescription antibacterial drug.
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595042 |
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07513207 |
A Study in Healthy People to Test How Vicadrostat Affects the Heart |
RECRUITING | PHASE1 |
| NCT07305831 |
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) |
COMPLETED | PHASE1 |
| NCT07272629 |
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants. |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05893862 |
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019) |
COMPLETED | PHASE1 |
| NCT04310930 |
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment |
RECRUITING | PHASE2/PHASE3 |
